University of Northern Iowa

UNI ScholarWorks
Honors Program Theses

Honors Program

5-2020

Literature review: The role of inflammatory biomarkers in the
connections between sleep and chronic health conditions
Madeline Walker
University of Northern Iowa

Let us know how access to this document benefits you
Copyright ©2020 Madeline Walker
Follow this and additional works at: https://scholarworks.uni.edu/hpt
Part of the Biochemistry Commons

Recommended Citation
Walker, Madeline, "Literature review: The role of inflammatory biomarkers in the connections between
sleep and chronic health conditions" (2020). Honors Program Theses. 428.
https://scholarworks.uni.edu/hpt/428

This Open Access Honors Program Thesis is brought to you for free and open access by the Honors Program at
UNI ScholarWorks. It has been accepted for inclusion in Honors Program Theses by an authorized administrator of
UNI ScholarWorks. For more information, please contact scholarworks@uni.edu.

LITERATURE REVIEW: THE ROLE OF INFLAMMATORY BIOMARKERS IN THE
CONNECTIONS BETWEEN SLEEP AND CHRONIC HEALTH CONDITIONS

A Thesis Submitted
in Partial Fulfillment
of the Requirements for the Designation
University Honors

Madeline Walker
University of Northern Iowa
May 2020

This Study by: Madeline Walker
Entitled: The Role of Inflammatory Biomarkers in the Connections between Sleep and Chronic
Health Conditions

has been approved as meeting the thesis or project requirement for the Designation
University Honors with Distinction or University Honors (select appropriate designation)

________
Date

________________________________________
Dr. Dilbur D. Arsiwalla, Honors Thesis Advisor

________
Date

______________________________________________________
Dr. Jessica Moon, Director, University Honors Program

SLEEP, INFLAMMATION, AND EFFECT ON CHRONIC DISEASE

1

Introduction
Decades of research has shown that sleep plays a vital role in our health, and disruptions
in sleep can have long term detrimental effects on our lives (Yoo, 2007). The recommended
amount of sleep by the National Sleep Foundation (NSF) for adults is between 7-9 hours each
night (NSF, 2020). It is common knowledge that too few hours of sleep are unhealthy, but
scientists are only beginning to understand the mechanisms that explain the connections between
sleep patterns and health outcomes (CDC, 2011). Additionally, recent research has shown that
excess sleep can be just as detrimental, if not more, to health outcomes (Patel, 2009). One of the
reasons that poor sleep can be a negative consequence for health is because sleep disruptions can
lead to inflammation (Patel, 2009). Inflammation is often a positive event that is occurring in the
body because it signifies that the body is healing. When a person gets a cut, the area around the
wound becomes inflamed because inflammatory biomarkers are being called to the area to
promote repair. However, too much inflammation can have negative consequences. If a person is
consistently getting poor sleep, then their body believes that it is constantly needing repair. This
activates the immune system and the previously mentioned inflammatory biomarkers are called
to respond (Mullington, 2010). These biomarkers, which normally help to heal areas of damage,
might cause the immune system to attack areas of healthy tissue, therefore causing damage rather
than repairing damage. Therefore, it is important to understand how this affects chronic health.
Chronic disease and inflammatory processes often coincide. When a patient has a chronic health
condition, their immune system is activated and is sending inflammatory biomarkers to respond
(Laveti, 2013). However, the question of whether the elevated levels of biomarkers are a side
effect of the chronic disease or a cause of the disease is unknown. If it is a cause, then it is
possible that poor sleep resulting in high levels of biomarkers could lead to chronic disease. In
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the current review, research on the effects of inflammatory biomarkers that are elevated as a
result of sleep is examined as well as the role that these biomarkers play in the increased risk for
chronic health diseases.
Review of Literature
To begin this review, it is necessary to understand the process of inflammation and the
role it plays in the body. The three biomarkers that will be discussed all have their own functions
during the inflammatory response, and in order to evaluate the effect that they have on sleep and
chronic disease, these jobs need to be fully understood. Once the biomarkers are discussed, the
relationship that they have with sleep will be discussed. There are many aspects of sleep to
examine including sleep duration, sleep efficiency, and sleep disorders. Research has shown that
sleep impacts biomarker levels, but it needs to be further examined to determine how this can
affect chronic disease (Patel, 2009). Chronic health issues are associated with inflammatory
biomarkers, but this relationship will be discussed further in order to determine the process
through which sleep predicts chronic health conditions via inflammatory biomarkers (Laveti,
2013). At the end of this review, the relationship between these three variables, sleep,
inflammatory biomarkers, and chronic health disease, will be discussed.
Inflammatory Biomarkers
Inflammation is the body’s reaction to invasion or infection. If either event occurs, the
body signals the immune system to repair damaged tissue (Szalay, 2019). Cytokines are the
actual components that signal the immune system to respond in a specific area of the body that is
being invaded. They are involved in cell signaling and ultimately leave a chemical trail, leading
the different molecules involved in healing to the area of injury (Black, 2004). When cytokines
are elevated, this indicates that the body’s immune system has been triggered, and there is
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inflammation occurring somewhere in the body. Numerous cytokines are being studied regarding
their relationship to chronic inflammation and sleep. The current review focuses on the
inflammatory biomarkers, C-Reactive Protein (CRP), Interleukin-6 (IL-6), and Tumor Necrosis
Factor-alpha (TNF-𝛼) since prior literature has emphasized their connections with sleep issues
and chronic health outcomes.
C-Reactive Protein
One crucial inflammatory biomarker is C-reactive protein. CRP is a plasma protein that is
actively involved in the body’s systemic response to inflammation. Many inflammatory
biomarkers have multiple effects as a result of a single gene and this includes CRP because it has
both proinflammatory and anti-inflammatory effects (Black, 2004). CRP affects inflammation
through the role it plays in the complement system, which is a pathway that causes inflammation
to occur (Black, 2004). CRP can mediate the pathway by binding to specific carbohydrates. This
leads to the release of proinflammatory cytokines which as mentioned earlier, attract white blood
cells to the area that requires healing. When CRP binds to the carbohydrate it causes
opsonization of the target cell. Opsonization is the process by which a cell is coated so that
macrophages, a type of white blood cell, can easily engulf and break down the cell through the
process called phagocytosis. Phagocytosis is then upregulated meaning macrophages ingest
foreign particles and remove them from the cell tissue (Black, 2004). This then causes an
elevation in serum levels, therefore indicating the occurrence of an inflammatory response.
With each acute inflammation stimulus, the plasma level of CRP may rise as much as
1000-fold and more (Black, 2004). These CRP levels are used as a test by medical professionals
in order to predict a patient’s risk of developing cardiovascular disease in the future. According
to the American Heart Association, CRP tests are beneficial in predicting the risk of patients who

SLEEP, INFLAMMATION, AND EFFECT ON CHRONIC DISEASE

4

have a 5-10% chance of having a heart attack in the next ten years (Mayo Clinic, 2017). This test
is also used to predict risk of having a second heart attack in patients who have already
experienced their first heart attack. Studies have found that CRP levels also have a strong
positive correlation with body mass index (BMI) a common risk factor for cardiovascular
disease(Pepys & Hirschfield, 2003). Regarding its relationship to other relevant cytokines, CRP
production in the liver is regulated by IL-6 (Black, 2004). An increase in CRP leads to an
increase in other biomarkers as well, such as IL-6 and TNF-𝛼 levels.
Interleukin-6
A second cytokine that plays a significant role in the inflammatory process is interleukin6, or IL-6. IL-6 attracts white blood cells to the area that needs healing during inflammation and
promotes accumulation of these cells (Barnes, 2011). White blood cells are agents of the immune
system that respond to and fight off infection in order to protect the body. IL-6 also promotes Bcell activity meaning that additional antibodies are produced in the body to help fight off foreign
invaders (Barnes, 2011). B-cells are a specific branch of white blood cells that are created to
produce antibodies. IL-6 not only affects B-cells, but it affects T-cells, another type of white
blood cell. T-cells target and destroy abnormal cells in the body and typically require strict
regulation in order to limit the number of cells they kill. However, IL-6 rescues T-cells from cell
death, or apoptosis (Barnes, 2011). If T-cells are not being readily destroyed, then they can turn
to healthy cells to attack. Therefore, it is suspected that IL-6 is involved in autoimmune diseases
because they increase the number of T-cells in our bodies (Barnes, 2011). IL-6 is also considered
one of the “chief stimulators” in the production of acute-phase proteins, which are the plasma
proteins whose concentrations vary during acute inflammatory responses (Gabay, 2006). Acute
inflammation is inflammation that is temporary, for example when a person falls and scrapes
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their knee. Chronic inflammation, on the other hand, is inflammation that is long term and
present throughout a person’s life. The main switch from acute inflammation to chronic
inflammation is the recruitment of monocytes, a type of white blood cell, to the area of injury
(Gabay, 2006). The recruitment of monocytes is one of the functions of IL-6 and therefore, IL-6
is thought to be the key player in the transition from acute inflammation to chronic inflammation.
During chronic inflammation, IL-6 then induces an innate immune response to affected cells and
an adaptive immune response directed against reinfection (Gabay, 2006). Innate immune
responses are the responses that every person has at birth (NCBI, 2016). It is our natural response
to foreign invaders. Adaptive immune response is the response that is saved after the initial
exposure, so that our body knows how best to fight off infection when re-exposed at a later point
in life (NCBI, 2016). Overall, IL-6 has been shown to be positively associated with inflammation
in the body, and its serum levels could be used to indicate related chronic diseases. As mentioned
previously, the other type of inflammatory biomarker affected by CRP is TNF-⍺.
Tumor Necrosis Factor-alpha
Tumor Necrosis Factor-alpha (TNF-⍺) is another biomarker that plays a vital role in the
process of inflammation. It was initially discovered for its antitumor activity but is now known to
be an inflammatory mediator (Sethi & Aggarwal, 2008). It is a protein that is produced by white
blood cells and eventually leads to the activation of other inflammatory genes (Popa, 2007). It is
considered the most abundant early mediator at the site of injury and is the “master regulator” in
pro-inflammatory cytokine production (Parameswaran & Patial, 2010). TNF-⍺ is produced by
both monocytes and macrophages, and as it is produced, it activates other macrophages
(Parameswaran & Patial, 2010). If there are high levels of TNF-⍺, then it is known that there has
been an activation of inflammation. Other studies report that TNF-⍺ induces changes in both

SLEEP, INFLAMMATION, AND EFFECT ON CHRONIC DISEASE

6

lipid and glucose metabolism. It has inhibitory effects on insulin receptors, which can lead to
diabetes, a risk factor for heart disease (Popa, 2007). It has also been shown to contribute to
atherosclerosis for numerous reasons including recruitment and activation of white blood cells
and other inflammatory molecules, promoting the expression of different adhesion molecules in
vessel walls, and causing an inflammatory cascade inside arterial walls (Popa, 2007). TNF-⍺
clearly plays a major role in the activation and regulation of inflammation, and several factors
point to the suspicion that it can indicate cardiovascular risk factors and disease.
Each of these three inflammatory biomarkers are a result of chronic inflammation. If the
biomarkers are elevated in the body, then this means that the body’s defense mechanism, white
blood cells, are being called to an area to destroy infection or invaders. If there are no obvious
foreigners, then it is thought that the white blood cells turn to healthy cell tissue and work to
destroy it (Szalay, 2019). Sleep deprivation is thought to be one of the inducers of these
biomarkers, therefore attracting of white blood cells over long periods of time (Trott et. al.,
2012). This ultimately affects the overall health of an individual and can increase the risk of
chronic diseases.
Sleep Duration, Quality, and Disorders and the Relationship to Inflammatory Biomarkers
Sleep disruptions are examined in terms of sleep duration, quality, and disorders. Recent
research suggests that both acute and ongoing sleep disruptions have a negative impact on one’s
health in the short term and in terms of long term outcomes as indicated by increased risk for
obesity, coronary artery disease, diabetes, and mortality (Patel, 2009). One commonly used
method is polysomnography, which assess brain electrical activity, airflow, respiratory effort,
and other physiological measures to determine sleep patterns. Commonly used indicators of
sleep quality from polysomnography recordings include sleep onset latency (or the amount of
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time it takes a person to fall asleep), the number of wake episodes a person experiences
throughout the night, and how long those wake episodes are. These can impact the efficiency of a
person’s sleep each night. Sleep efficiency is defined as the ratio of total sleep time to total time
in bed (Reed & Sacco, 2016). Total sleep time is the time spent sleeping as opposed to the time
spent watching TV, looking on one’s phone, reading, etc. (Reed & Sacco, 2016). Another way
that sleep duration is commonly assessed is by using self-reported habitual sleep time (Reed &
Sacco, 2016). This method is less reliable than a polysomnography due to the influence of social
desirability bias and fallibility of human memory. Additionally, people may overestimate or
underestimate their self-reported sleep patterns (Lauderdale, 2008). While many people may
experience a low sleep efficiency or poor duration of sleep on its own, sleep disorders can also
cause issues in these two areas.
Duration and quality of sleep are disrupted by sleep disorders which is defined as any
condition that changes the way you sleep and has an overall negative impact on your health
(Mayo Clinic, 2019). Insomnia is one of the most common sleeping disorders (Basta, 2007).
Statistics show that 25-33% of the population complains of difficulty falling asleep or difficulty
staying asleep and around 10% complain of this being a chronic issue. Insomnia is often not
discussed in society today and it is found that somewhere around 60% of all insomniacs do not
seek medical assistance (Basta, 2007). Because of the lack of treatment, insomnia has large
implications on public health.
Another sleeping disorder that may be associated with cardiovascular disease and
mortality risk and is obstructive sleep apnea (Motamedi et.al., 2009). Sleep apnea is when a
person’s sleep is disturbed multiple times during the night due to an obstruction in respiration
often due to the collapse of the nasal passageway. It is estimated that 20% of all adults have a
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mild form of sleep apnea and 7% of the population have moderate or severe symptoms
(Motamedi et.al., 2009). When sleep apnea occurs, it interrupts the sleep cycle leading to
fragmented sleep wherein the patient may experience apnea (complete cessation of breathing) or
hypopnea (partial cessation of breathing) for more than 30 times an hour in cases of severe apnea
(Ruehland, 2009).
Restless Leg Syndrome is another sleep disorder that may be related to chronic disease.
Patients with restless leg syndrome experience an urge to move their legs while at rest,
particularly at night (Trott et. al., 2012). This disrupts sleep patterns and is suspected to be
associated with elevated inflammatory markers. The final sleep disorder that will be discussed is
nightmare disorder which is defined as the repeated occurrence of nightmares that cause distress
and cannot be attributed to another mental health disorder or substance use (American
Psychiatric Association, 2017). Nightmares occur during REM sleep and are generally associated
with symptoms of physical arousal. Nightmares often lead to awakenings, but this is not required
to be diagnosed with a nightmare disorder. A nightmare sleep disorder is recognized as having
one or more episodes per week lasting one to six months (Gieselmann et.al., 2019). It is
suggested that these sleep disorders indicate a higher risk for future chronic conditions due to the
disruption of sleep and the effect it has on inflammatory biomarkers such as C-reactive protein,
Interleukin-6, and Tumor Necrosis Factor-⍺.
Several studies involving sleep duration, sleep quality, and sleep disorders, many of
which resulted in elevated CRP, IL-6, and TNF- 𝛼 and are summarized in Table 1. In studies
looking at sleep duration, whether it be above or below the recommended amount of sleep, it was
often found that there was elevated CRP (See Table 1). One study noted a U-shaped curve in
results with CRP spiking at greater than 9 hours of sleep and less than 5 hours of sleep
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(Grandner, 2013). However, one interesting finding in this study was that women tended to have
elevated CRP with greater than 9 hours of sleep and men tended to have elevated CRP with less
than 5 hours of sleep. Averaging these results among the overall population resulted in the Ushaped curve but splitting by gender resulted in only one end of the spectrum showing elevation
in CRP levels. Patel’s study (2009) found similar results with elevated CRP secondary to sleep
that was greater than 9 hours. They also found elevations in IL-6 with long durations of sleep
while TNF-𝛼 in participants who had shortened sleep duration (Patel, 2009). Shearer and
colleagues (2001) studied participants’ levels of IL-6 and TNF-𝛼 and found increased levels with
sleep loss. Similar to this, another study showed elevated CRP levels with sleep loss (MeierEwert, 2004). Overall, most studies generally agree with the findings that any amount of sleep
outside the usual 6-9 hours can lead to increased cytokine levels in the blood (see Table 1).
However, there have been a couple of studies that have found contradicting results as well.
Frey’s results showed that there were decreased levels of CRP and IL-6 when participants
suffered from sleep deprivation, however they did note several other inflammatory biomarkers
were elevated instead (2007).
Sleep quality may also be a factor that is associated with increased inflammatory
biomarker levels as shown in Table 1One study examined social connections and sleep
efficiency and how that impacted levels of IL-6 (Friedman, 2005). Social connections and sleep
efficiency were measured using a self-report survey and the participants were also given a health
assessment by a professional (Friedman, 2005). This study found that women with good social
connections and good sleep efficiency had relatively low levels of IL-6 whereas women with
poor social connections and poor sleep efficiency had noticeably higher levels of IL-6
(Friedman, 2005). Women with some combination of the two options had similarly low levels of
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IL-6 as those who had both good social connections and good sleep efficiency (Friedman, 2005).
Additionally, studies observed sleep quality using an electroencephalogram to measure brain
waves and determine which stages of sleep the participant was experiencing (Hong, 2005). Poor
sleep included several episodes of disrupted sleep and complaints of fatigue the following
morning. They found that patients with lower sleep efficiency had higher levels of IL-6 the
following morning than those patients with higher sleep efficiency (Hong, 2005). Both studies
found elevated levels with decreased sleep efficiency. Although one would expect that
Friedman’s study would find elevated levels with those participants with poor sleep efficiency
and good social connections rather than only those who were rated as poor in both categories.
This could be unreliable information, meaning that the results are not scientifically correct, as it
is very difficult to measure one’s own sleep quality. Hong’s study (2005) was able to measure
sleep efficiency using an EEG as well as self-report.
Most research on the associations between sleep and inflammatory biomarkers focuses on
several sleeping disorders including sleep apnea, insomnia, restless leg syndrome, and more.
Razhegi (2011) conducted a broader study that focused on insomnia, restless leg syndrome,
nightmares, narcolepsy, sleep apnea, and sleepwalking in dialysis patients. They used dialysis
patients because they had noticed a pattern of sleep disorders among that group. When
comparing CRP levels to those of a control group, the researchers found a notable elevation
(Razhegi, 2011). One study with a particular focus on sleep apnea found that CRP levels were
elevated in children who struggle with sleep apnea, and it was particularly high in those that
complained of sleepiness and fatigue the following morning (Tauman, 2004). Another similar
study found elevated levels of IL-6 and TNF-𝛼 in adult males with obstructive sleep apnea as
compared to the control and they concluded that this could provide evidence that there is a
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correlation to cardiovascular comorbidities (Ciftci, 2004). Other disorders besides sleep apnea
have also been studied such as insomnia. Burgos and colleagues in 2005 used polysomnography
to study patients with primary insomnia several days in a row. They measured serum levels of
IL-6 during the evening and late at night and compared these serum levels to patients without
any sleeping disorders. Their results showed a noticeable elevation of IL-6 levels in patients with
primary insomnia (Burgos, 2005). On the other hand, patients with restless leg syndrome were
found to have no correlating IL-6 or TNF-𝛼 levels, but elevated CRP levels were observed
(Trotti et. al., 2012). Elevated cytokine levels were found in many research studies, not just those
that were mentioned. Most provide support towards the theory that sleep does affect
inflammation and poor sleep patterns could lead to a rise in inflammatory biomarkers (see Table
1). Several studies have shown that factors such as sleep duration, sleep quality, and various
sleep disorders can all lead to this elevation. The question at hand is whether this elevation in
biomarker levels can further lead to things such as chronic diseases.
Chronic Health Outcomes
Disease can be classified into two main categories, acute versus chronic. The current
review focuses primarily on chronic disease and how it relates to increased inflammatory
markers. Chronic disease is any disease or illness that is long developing and ongoing whereas
acute disease is a sudden onset episode. Frequently, in case of chronic disease, patients will
experience an acute exacerbation of symptoms that can be life-threatening. Patients with chronic
diseases tend to have elevated inflammatory markers over extended periods because the body is
undergoing stress from their disease, and their immune system is on constant overdrive (Pahwa,
2019). This elevation of inflammatory biomarkers can have severe consequences on a person’s
overall health and may lead to health problems such as cardiovascular disease and strokes.
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Cardiovascular Disease (CVD)
The leading cause of death in the United States today is cardiovascular disease.
Cardiovascular disease includes any issues with the heart such as heart attacks, coronary artery
disease, congestive heart failure, arrhythmias, and heart valve problems (American Heart
Association, 2014). Cardiovascular disease leads to damage to the heart which in turn triggers an
immune response causing white blood cells to attack cardiac muscle (Ludwig-MaximiliansUniversität München, 2017). One factor linked to cardiovascular disease is an increased level of
cytokines such as IL-6, TNF-𝛼, and CRP. These inflammatory biomarkers have
proinflammatory, procoagulant (promotion of blood clotting), and growth promoting effects.
They are produced directly in the arterial wall when elevated due to factors such as smoking and
alcohol consumption (Mendall, 1997). TNF-𝛼 has been found to be associated with body mass
index (BMI) which is also a common cardiac risk factor (Mendall, 1997). Another study
suggested that CRP may be a more significant biological risk factor of heart disease than
cholesterol as previously believed (Notarangelo, 2017). In order to develop heart disease,
cholesterol first must be modified before it leads to plaque formation on the arterial walls. The
plaque is recognized as a “foreign body” and the immune system is then triggered, sending out
inflammatory biomarkers such as CRP to respond to the attack (Notarangelo, 2017). Elevation of
these inflammatory biomarkers can destroy the cell wall as it attacks the plaque and cholesterol,
and this causes damage to the blood vessels creating an increased risk for heart attacks
(Notarangelo, 2017). This implies a positive correlation between elevated inflammatory
biomarkers and cardiovascular disease.
When looking deeper into studies, the correlation becomes more apparent, particularly
with CRP. Table 2 summarizes trends of several studies that found relationships between
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elevated CRP levels in patients either before or after experiencing a stroke or a cardiovascular
issue such as coronary artery disease, acute coronary syndrome, myocardial infarction, or angina.
Biasucci (2004) noted in their study of patients at the time of admission to the coronary unit in
the hospital that there was a relationship between elevated IL-6 and elevated CRP, thus
confirming the relevance of cytokine influence on the prognosis of unstable angina. They also
reported that medications used to treat acute coronary syndrome were found to be most effective
for lowering cardiac risk in patients who initially had high CRP levels (Biasucci, 2004). Another
study analyzed a larger pool of patients who have already had experiences with CVD and noted
that CRP blood levels showed consistent associations in those patients, although it was unclear
as to the exact relationship between CVD and CRP elevation (Kaptoge, 2010).
Similar studies also found elevations in IL-6 and TNF-𝛼 to patients who have
experienced a cardiovascular event (See Table 2). IL-6 was associated with increased
atherosclerosis, which occurs when fatty plaque is deposited inside the artery walls (Kato, 2002).
This is consistent with the discussion of the effect that IL-6 has on the development of CVD
since atherosclerosis causes vessel diameter to decrease and eventually leads to CVD (Mayo
Clinic, 2018). Because IL-6 increases as plaque buildup increases in the vessel walls, IL-6 could
be an indicator of oncoming cardiac disease. As for TNF-𝛼, studies have shown that the presence
it has in cardiac tissue suggests that it plays a role in the pathogenesis of cardiomyopathy, thus
possibly being another indicator of CVD (Habib, 1996). Because these studies generally follow
up on patients after a CVD event has occurred, it is difficult to conclude that these mentioned
biomarkers affect the body which eventually leads to CVD or whether they are just signs that the
body has had damage from the disease. In other words, do the elevated biomarkers cause the
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disease or does CVD cause the elevated biomarkers due to the amount of stress and repair it is
undergoing?
While these particular reports studied patients only after they have experienced CVD,
longitudinal studies have also been done in order to examine change over time. One group of
researchers performed a longitudinal study over the course of 17 years on high risk, but healthy
patients with follow-ups to look for death or myocardial infarctions (Kuller, 1996). They found a
significant correlation between those patients with both elevated CRP and later developing CVD
(Kuller, 1996). This study stood out since they focused on outcomes over an extended period and
for following CRP levels prior to a heart attack or cardiovascular problem leading to death. Other
factors were also accounted for in order to rule out the risk factors as being the only cause. For
example, they found that CRP was notably elevated in smokers, even after accounting for the
different factors that could affect their risk, such as the number of cigarettes per day or how long
they have been a smoker (Kuller, 1996). This was again shown in another pre-CVD study as well
as involving IL-6. This study was broad and observed the interleukin levels in over 14,000 men
who were considered healthy. The patients who eventually had myocardial infarctions were
observed to have increased IL-6 (Ridker, 2000). In addition to CVD, another health problem that
is affected by chronic inflammation is a cerebrovascular accident.
Strokes
A cerebrovascular accident, commonly known as a stroke, occurs when there is a lack of
blood flow to the brain which causes active ischemia to cranial tissue. This is typically caused by
a blocked vessel that supplies blood to the brain or by bleeding in the brain. Sleep is commonly
believed to be a predictor of stroke risk. Studies have shown that short amounts of sleep
increased risk by 18% while extended amounts of sleep increased the risk of stroke by 46% after
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accounting for cardiovascular risk factors and comorbidities (Leng 2018). This risk is nearly
twice the risk of a patient receiving the proper amount of sleep each night. In addition to these
findings, there is also an association between patients who experience chronic inflammatory
diseases such as systemic lupus erythematosus and rheumatoid arthritis, and those who
experience strokes (Kamel & Iadecola, 2017). Patients who have these inflammatory illnesses
have a significantly increased risk of having a stroke as compared to those with the common risk
factors (Kamel & Iadecola, 2017). This raises the question of whether elevated inflammatory
biomarkers such as CRP, IL-6, and TNF-𝛼 have implications for increased risk for having a
stroke.
After analyzing several studies, a similar pattern was found between cytokine levels and
strokes as was found with CVD (see Table 2). For example, Tancin Lambert and colleagues
(2020) studied stroke patients with atrial fibrillation. This condition is a major risk factor for
having a stroke, and they found that there were numerous cytokines that were associated with
atrial fibrillation. They determined that there was a strong possibility that IL-6 could be very
useful in identifying atrial fibrillation in patients which relates to strokes since almost a quarter
of all strokes are related to atrial fibrillation (American Heart Association, 2017). Reports that
studied TNF-α also examined risk factors of strokes and the TNF-α showing a positive
association with typical risk factors such as cholesterol, blood pressure, age, smoking, and BMI
(Cui, 2012). In demonstrating the relationship between these biomarkers and common risk
factors, it becomes more evident that there could be an association between elevated biomarkers
and the prognosis of strokes. However, risk factors were not the only aspect examined; patients
with strokes were studied as well. Whiteley completed a three-year study from 2002-2005
involving follow-ups with patients post-stroke in order to test for CRP and IL-6 levels in the
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blood as well as the outcomes of the cases. It was found that elevated levels were associated with
poor outcomes later in life, although they could not determine a model to predict recurrent
strokes or outcomes (Whiteley, 2005). Several other studies showed results consistent with these
outcomes, as seen in Table 1.
Overall, it is clear that there is an association between inflammatory biomarkers and
chronic health outcomes, but a definite relationship cannot be established for several reasons.
Multiple studies addressed their limitations, but in many cases the limitations impede the
findings. Many studies had very small sample sizes due to the availability of patients or difficulty
recruiting patients. Without larger sample sizes, results may be affected due to increased margin
of error and decreased representation of the population. Even in those studies that had large
sample sizes, problems with causation versus correlation were apparent. Many studies only
included patients after they have experienced an acute health crisis. By that point most of them
already had elevated biomarker levels, and it cannot be determined whether the biomarkers were
elevated prior to the event or after the event. This is due to not being able to accurately predict
the who, what, or when of a health crisis. When you are unsure if someone will eventually have a
stroke, it is difficult to collect data. Some research addressed both issues and included large
sample sizes as well as using longitudinal studies of high-risk patients who may or may not
develop CVD or stroke. However, even with these studies it can be challenging to show that the
inflammatory biomarkers are elevated because the patient is about to have an acute crisis or if
they are elevated for some other reason in the body such as hypertension or high cholesterol
which are risk factors of many chronic health problems. There is a positive correlation between
inflammation and chronic disease, although determining whether there is a causal effect would
require more research to be done. Also, due to ethical concerns with conducting experiments for
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high risk factors, the effect of inflammation on chronic disease cannot be easily examined since
researchers cannot experimentally manipulate these variables. This correlation can be related
back to the discussion of sleep and its impact on inflammation. Poor sleep can lead to an
elevation of inflammatory biomarkers in the body and having these biomarkers being elevated
chronically may lead to the development of chronic health disease.
Conclusion
Based on prior research on the relationship between sleep and inflammatory biomarker
levels as well as between chronic health disease and inflammatory biomarker levels, several
conclusions may be drawn. When first examining the effects of sleep on inflammation, it can be
concluded that several factors leading to an unusual amount of sleep, or to disturbed sleep,
causing the body to respond by signaling the release of inflammatory markers. Studies have
consistently found elevations in CRP, IL-6, and TNF-𝛼 when sleep duration was altered, sleep
quality was decreased, or in patients with several different sleep disorders. If a person is
consistently experiencing these different effects, then the body will also continuously be
experiencing an inflammatory response. As mentioned earlier, the release of these biomarkers
can be beneficial when there is a need for repair and healing in the body. However, when there is
no need for inflammation, these biomarkers have no specific location to go to, and they will
spread out and begin attacking healthy tissue, which will have negative consequences on the
body.
When looking at the effects of inflammation on chronic disease, it becomes more
challenging to make a definitive conclusion. While many studies point towards an association
between the two, most are unable to establish a clear causal connection due to ethical reasons
since inflammation cannot be experimental manipulated in experimental settings. In many
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studies, it is undetermined whether the inflammation levels came first and caused the chronic
disease or worsened chronic disease or whether the chronic health disease is causing
inflammation to increase inside the body. In order to determine this, more experimental
longitudinal studies need to be conducted. If researchers can begin by looking at inflammatory
biomarker levels in patients throughout their lifetime, they will be able to see how these levels
are affected before and after they develop chronic disease and compare these results to patients
experiencing similar problems. The challenge with this is that not only does it take time to
conduct longitudinal studies, but it is also difficult to control factors that may cause different
reactions in patients, such as stress levels, careers, living locations, etc. Without being able to
control these factors, it may never be known definitively whether the elevated cytokine levels are
increasing the risk of chronic diseases or if other factors that lead to chronic disease.
Although it can be established that sleep does impact levels of inflammatory biomarkers
in the body, it is difficult to say whether those elevated biomarkers do lead to chronic diseases.
There is still a lack of clarity that this very well could be the case due to the handful of
longitudinal studies done regarding chronic disease and biomarker levels. These studies, as
mentioned earlier, have found that there is a positive association between the two variables, and
this could potentially indicate that chronically elevated biomarkers may increase the risk of
developing chronic disease later in life. Because the biomarkers are elevated, this means that the
body’s immune system is active. However, when there is no apparent reason for it to be active,
the body is attacking cells that do not need to be destroyed. As a result, this attack can lead to the
destruction of vessels and tissue that is vital to keep intact in order to stay in good health. Sleep
changes may predict an increase in inflammatory biomarker levels, but the question at hand is
whether this, in turn, increases the risk of developing chronic diseases. While this does seem to
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be the cause, more research needs to be conducted about the causal effect between inflammatory
biomarkers and chronic health problems to confidently come to this conclusion. Until there is
extensive research in this area, it cannot be confirmed that the lack of quality sleep can lead to
chronic diseases. Although a definitive relationship cannot yet be fully established, these results
show significant promise regarding the future of sleep studies and health. By understanding how
inflammation impacts chronic health disease, other issues that affect inflammation can also be
studied and identified as causes of chronic health disease. This research also highlights the
importance of studying sleep and how adjusting one’s sleep is a simple way to live a healthier
life and decrease the risk of poor health in the future. These findings could be used to emphasize
sleep disorder interventions as a method to reduce inflammation in patients who suffer from
chronic disease. Overall, these studies could change the way health professionals talk about sleep
and other causes of inflammation and emphasize the long-term impact that it can have on a
person’s body and health.
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Appendix
Table 1
Studies Focused on Sleep and Inflammatory Biomarkers
Study
Burgos
Firat Guven
Frey
Friedman
Grandner

Year
2005
2012
2007
2005
2013

Sample
Size
22
76
19
74
5587

Sleep Disorder
Insomnia
Sleep Apnea
Sleep Deprivation
Sleep Efficiency
Sleep Duration

CRP
N/A
Elevated
Decrease
N/A
Elevated

IL-6
Elevated
N/A
Decrease
Elevated
N/A

TNF-⍺
N/A
N/A
N/A
N/A
N/A

Guilleminault
Hong
Kaditis
Kokturk

2004
2005
2005
2005

239
70
141
173

Sleep Apnea
Sleep Quality
Sleep Apnea
Sleep Apnea

Elevated
N/A
No relationship
Elevated

N/A
Elevated
N/A
N/A

N/A
N/A
N/A
N/A

Larkin
Meier-Ewert

2005
2004

143
20

Sleep Apnea
Sleep Loss

Elevated
Elevated

N/A
N/A

N/A
N/A

Patel
Razeghi
Schiza
Shearer
Song
Tauman
Trotti
Ciftci
Vgontzas
Vgontzas

2009
2012
2010
2001
1998
2004
2012
2004
2004
1997

614
108
528
42
30
81
137
43
25
41

Sleep Duration
Sleep Disorders
Sleep Apnea
Sleep Loss
Sleep Disorders
Sleep Apnea
Restless Leg Syndrome
Sleep Apnea
Sleep Restriction
Sleep Disorders

Elevated with long duration
Elevated
Reduced with CPAP
N/A
N/A
Elevated
Elevated
N/A
N/A
N/A

Elevated with long duration
N/A
N/A
Elevated
Elevated
N/A
No correlation
Elevated
Elevated
Elevated

Elevated with short duration
N/A
N/A
Elevated
N/A
N/A
No correlation
Elevated
Elevated in men
Elevated
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Table 2:
Studies Focused on Chronic Health and Disease and Inflammatory Biomarkers
Study
Biasucci et al.
Bokhari et al.
Ma et al.
Benamer et al.
Eshaghi et al.
Jenny et al.
Kuller et al.
Kaptoge et al.
Liuzzo et al.
Mendall et al.
Napoli et al.
Ridker et al.
Lindmark et al.
Kato et al.
Tancin Lambert et al.
Volpato et al.
Whiteley et al.
Woodward et al.
Zimmermann et al.
Zempelas et al.
Smith and Allen
Habib et al.
Latini et al.
Cui et al.

Year
2004
2014
2020
1998
2019
2002
1996
2010
1994
1997
2001
2000
2001
2002
2020
2001
2009
1999
1998
2005
1992
1996
1994
2012

Sample Size
67 patients
131 patients
588 patients
195 patients
618 Patients
5201 patients
737 patients
160,309 patients
92 patients
198 Patients
193 Patients
14,916 patients
3489 patients
156 patients
26 patients
620 patients
844 patients
1574 patients
280 patients
1514 patients
Mice, unknown
40 patients
18 patients
2415 patients

CVD or Stroke
CVD
Stroke
Stroke
CVD
CVD
CVD
CVD
CVD and Stroke
CVD
CVD
Stroke
CVD
CVD
CVD
stroke
CVD
stroke
CVD
CVD
CVD
CVD
CVD
CVD
Stroke

CRP
Elevated
N/A
Elevated
No correlation
Elevated
n/a
Elevated
Elevated
Elevated
N/A
Elevated
Elevated
N/A
N/A
N/A
N/A
Elevated
N/A
Elevated
33% lower CRP
N/A
N/A
N/A
N/A

IL-6
Elevated
N/A
Elevated
N/A
N/A
Elevated- 5%
N/A
N/A
N/A
Elevated
N/A
Elevated
Elevated
Elevated
Elevated
Elevated
Elevated
Correlation
N/A
33% lower
N/A
N/A
N/A
N/A

TNF-⍺
N/A
Elevated
Elevated
N/A
N/A
N/A
N/A
N/A
N/A
Elevated
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
21% lower
Elevated
Elevated
Elevated
Elevated

